European Journal of Clinical Pharmacology

, Volume 64, Issue 2, pp 207–216

Disease progression, drug action and Parkinson’s disease: Why time cannot be ignored

Review Article

DOI: 10.1007/s00228-007-0427-9

Cite this article as:
Holford, N. & Nutt, J.G. Eur J Clin Pharmacol (2008) 64: 207. doi:10.1007/s00228-007-0427-9

Abbreviations

α

Slope of linear disease status curve

Ce

Effect compartment concentration

CeSS

Steady state effect site concentration at the start of each levodopa infusion derived from endogenous dopamine and previous exogenous levodopa administration

C0pnss

Non-steady state levodopa concentration in plasma

C0snss

Non-steady state component of the slow equilibration effect compartment

Dmax

Maximum levodopa induced response above baseline

Dvtpk

Duration of uniform diurnal input.

EC50

Concentration at which 50% of maximum response is produced.

Emax

Maximum tapping rates that a drug can produce.

Hill

Hill coefficient which determine the steepness of the concentration–response curve.

RDiurnal

Ratio of diurnal input to constant input of endogenous dopamine

Rsynd

Rate of levodopa equivalent dopamine synthesis in the dopa synthesis effect compartment during the diurnal input period

S0

Baseline status

Teqd

Equilibration half-life of the dopa synthesis effect compartment

Teqf

Equilibration half-life of the fast equilibration effect compartment

Teqs

Equilibration half-life of the slow equilibration effect compartment

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Department of Pharmacology and Clinical PharmacologyUniversity of AucklandAucklandNew Zealand
  2. 2.Department of NeurologyOregon Health and Science UniversityPortlandUSA

Personalised recommendations